166 related articles for article (PubMed ID: 7538528)
1. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
Gajewski TF; Renauld JC; Van Pel A; Boon T
J Immunol; 1995 Jun; 154(11):5637-48. PubMed ID: 7538528
[TBL] [Abstract][Full Text] [Related]
2. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
3. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.
Yang G; Hellström KE; Mizuno MT; Chen L
J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096
[TBL] [Abstract][Full Text] [Related]
4. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
5. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
6. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
7. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
[TBL] [Abstract][Full Text] [Related]
8. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
[TBL] [Abstract][Full Text] [Related]
9. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
10. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors.
Guerder S; Carding SR; Flavell RA
J Immunol; 1995 Dec; 155(11):5167-74. PubMed ID: 7594526
[TBL] [Abstract][Full Text] [Related]
11. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of anti-B7-1 and anti-M150 antibodies in restricting the delivery of costimulatory signals from B cells and macrophages.
Agrewala JN; Suvas S; Verma RK; Mishra GC
J Immunol; 1998 Feb; 160(3):1067-77. PubMed ID: 9570518
[TBL] [Abstract][Full Text] [Related]
13. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death.
Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL
Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322
[TBL] [Abstract][Full Text] [Related]
14. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
15. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
16. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 12 and B7/CD28 interaction synergistically upregulate interleukin 10 production by human T cells.
Peng X; Kasran A; Ceuppens JL
Cytokine; 1997 Jul; 9(7):499-506. PubMed ID: 9237812
[TBL] [Abstract][Full Text] [Related]
18. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors.
Liu B; Podack ER; Allison JP; Malek TR
J Immunol; 1996 Feb; 156(3):1117-25. PubMed ID: 8557987
[TBL] [Abstract][Full Text] [Related]
19. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
20. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.
Okamoto I; Kohno K; Tanimoto T; Ikegami H; Kurimoto M
J Immunol; 1999 Mar; 162(6):3202-11. PubMed ID: 10092771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
